Heart Diseases (Heart Disease)

Subscribe to Selected New Research on Heart Diseases

13044 relevant articles (515 outcomes, 1354 trials/studies) found for this Disease

Description: Pathological conditions involving the HEART including its structural and functional abnormalities.

Also Known As:

Heart Disease; Cardiac Disease; Cardiac Diseases; Disease, Cardiac; Disease, Heart; Diseases, Cardiac; Diseases, Heart

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Heart Failure
2.	Hypertension (High Blood Pressure)
3.	Neoplasms (Cancer)
4.	Atrial Fibrillation
5.	Stroke (Strokes)

Experts

1.	Salonen, Jukka T: 9 articles (08/2008 - 08/2002)
2.	Voutilainen, Sari: 8 articles (08/2008 - 08/2002)
3.	Mursu, Jaakko: 6 articles (08/2008 - 08/2004)
4.	Walsh, Edward P: 6 articles (04/2008 - 04/2003)
5.	Cheatham, John P: 5 articles (10/2008 - 03/2006)
6.	Berul, Charles I: 5 articles (04/2008 - 04/2003)
7.	Schaefer, Ernst J: 5 articles (12/2007 - 02/2002)
8.	Díez, Javier: 5 articles (11/2007 - 12/2002)
9.	Hsu, Daphne T: 5 articles (02/2007 - 02/2003)
10.	Cheng, Jun: 5 articles (11/2005 - 01/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Heart Diseases:

1.	CholesterolIBA 02/01/2006 - " For the best protection against clogged arteries and heart disease, average cholesterol no longer makes the grade--lower is better." 12/01/1995 - "A systematic examination of the evidence on the relationship between serum cholesterol and ischaemic heart disease shows conclusively that serum cholesterol reduction in populations with high rates of heart disease is an effective and safe method of reducing ischaemic heart disease rates. " 12/01/2005 - "OBJECTIVES: It is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and secondary prevention of heart disease. " 01/01/2007 - "RESULTS: The progressive improvement in cholesterol management in ischaemic heart disease (IHD) is used as an exemplar of the changes achieved. " 01/01/2007 - "Such seminal findings as the effects of smoking and high cholesterol on heart disease came from the Framingham Heart Study. " Order ALL the reference details at left...
2.	Amiodarone (Amiodarona)FDA LinkGeneric 11/01/1996 - "The combination of the two drug tests, electrophysiologic study and Holter monitoring, is a useful method for the prediction of the long-term efficacy of amiodarone in patients with sustained VT and underlying heart disease. " 01/01/2005 - "CONCLUSIONS: Amiodarone was more effective for preventing recurrence in patients with poorer left ventricular function and underlying heart disease." 11/01/1986 - "Thus, in patients with frequent VPCs and no underlying heart disease, oral intake of T3 during amiodarone treatment is safe and does not abolish the antiarrhythmic efficacy of amiodarone, despite a shortening of the QTc.(ABSTRACT TRUNCATED AT 250 WORDS)" 07/13/1999 - "BACKGROUND: Amiodarone is widely used in adults with congenital heart disease, but no systematic study has been published on its effects on thyroid function in these patients. " 06/01/1997 - "The aim of this study was to assess the influence of amiodarone hydrochloride on time- and frequency-domain parameters of signal-averaged electrocardiogram (SAECG) in patients with ischaemic heart disease (IHD). " Order ALL the reference details at left...
3.	Estrogens (Estrogen)FDA Link 11/25/1991 - "These benefits have not been established by a randomized trial, however, so that the degree of protection against heart disease might have been overestimated because estrogen users tend to be healthier than nonusers. " 07/09/1999 - "These novel observations may help to explain the role of estrogen in gender-based differences found in cardiac disease." 07/01/1997 - "OBJECTIVE: To assess the efficacy of unopposed estrogen, and three estrogen/progestin regimens on selected heart disease risk factors among adherent women and to contrast those results with efficacy among all women in the PEPI study. " 07/15/1994 - "Estrogen's protection against heart disease may be overstated." 01/01/2006 - "While these findings have led to a revision of guidelines such that they discourage the use of estrogen for primary or secondary prevention of heart disease in postmenopausal women, many investigators have attributed the negative results in clinical trials to several flaws in study design, including the older age of study participants and the initiation of estrogen late after menopause.Because" Order ALL the reference details at left...
4.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 04/01/1990 - "Further studies are required to establish the clinical importance of cardioprotection by ACE-inhibitors in ischaemic heart disease." 04/01/1990 - "However, these cardioprotective effects have not yet been shown in patients with ischaemic heart disease, although some studies indicate that ACE-inhibitors are also able to cause anti-ischaemic effects in patients. " 12/01/2008 - "Some of these changes can be summarized as follows: Basis therapy includes betablockers and - in patients with structural heart disease - ACE-inhibitors and AT(1)-Blockers respectively. " 04/01/2004 - "Patients with cardiac diseases and those treated with ACE inhibitors were excluded because of potential effects on LV performance. " 10/01/2003 - "Antithrombotic therapy, beta blockers, ACE inhibitors and statins have been shown to reduce mortality and cardiovascular morbidity in patients with ischaemic heart disease. " Order ALL the reference details at left...
5.	bosentan (Tracleer)FDA Link 11/01/2006 - "However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CHD). " 05/01/2007 - "OBJECTIVE: To evaluate safety, tolerability, and clinical and haemodynamic effects of bosentan in patients with PAH related to congenital heart disease (CHD). " 09/01/2006 - "Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD). " 09/01/2005 - "CONCLUSIONS: Treatment with bosentan in infants and young children with PAH due to congenital heart disease was tolerated without significant side effects and resulted in stabilization of clinical status. " 09/01/2008 - "In addition, bosentan has demonstrated efficacy in patients with congenital heart disease and Eisenmengers syndrome with right to left shunting and in HIV-related PAH. " Order ALL the reference details at left...
6.	Anti-Arrhythmia AgentsIBA 01/01/1991 - "Although there is good evidence in many forms of heart disease that complex VEBs indicate a high risk of death, treatment of asymptomatic VEBs with antiarrhythmic drugs has not been shown to improve survival and may be hazardous. " 10/01/2000 - "CONCLUSION: EAT in children without underlying heart disease can be effectively treated using antiarrhythmic drugs. " 02/01/1993 - "The clinical outcome is critically dependent on the type and degree of underlying heart disease, symptoms at presentation, inducibility at electrophysiology study, and responses to antiarrhythmic drugs. " 01/01/1990 - "This study was performed to evaluate the effects of antiarrhythmic drugs on left ventricular function in 843 patients with ischaemic heart disease and ventricular arrhythmias (Lown classes 2-5). " 11/01/2009 - "Patients with structural heart disease frequently take antiarrhythmic drugs (AADs), which directly affect repolarization. " Order ALL the reference details at left...
7.	Carnitine (L-Carnitine)FDA LinkGeneric 11/01/1999 - "Acute and chronic L-carnitine application exerts protective effects in a number of cardiac diseases. " 11/01/2004 - "L-carnitine, which is required for mitochondrial FFA transport/oxidation, has been reported to improve vascular function in subjects with diabetes and heart disease. " 03/01/2005 - "Hype for the dietary supplement carnitine as a treatment for heart disease far outstrips the evidence." 03/01/2005 - "Carnitine promising, but no miracle for heart disease. " 08/01/1998 - "These findings suggest that supplementation of L-carnitine has a beneficial effect on the isolated heart under various conditions, and possibly on specific human heart diseases." Order ALL the reference details at left...
8.	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/17/2009 - "What aspirin dose is safest and most effective for preventing heart disease?" 10/01/2001 - "Already used by millions of patients with heart diseases, aspirin could be a useful protection against contractile dysfunction of the obstructed bladder." 08/01/2009 - "This study characterised the prevalence of aspirin resistance in patients with ischaemic heart disease (IHD) and investigated the concordance and repeatability of these tests. " 12/01/2005 - "The objective of this study was to assess whether polymorphisms in UGT1A6 and CYP2C9 genes are related to the prevalence of upper gastrointestinal symptoms in cardiovascular patients using acetylsalicylic acid for secondary prevention of ischaemic heart disease. " 12/01/2005 - "This study was designed to assess the effect of daily 75 mg aspirin on platelet function, as measured by the PFA-100, in 92 patients with ischaemic heart disease. " Order ALL the reference details at left...
9.	AntioxidantsIBA 11/01/2002 - "CONCLUSION: The ability of antioxidants to inhibit these apoptotic pathways has raised the possibility of newer therapeutic treatment for various heart diseases." 04/01/2009 - "This study examined the relationship of hyperhomocysteinaemia with lipid profile and antioxidants in patients with ischaemic heart disease from rural areas in Maharashtra, India. " 01/01/2002 - "Polyphenol antioxidants in citrus juices: in vitro and in vivo studies relevant to heart disease." 12/01/1990 - "Plasma levels of major essential antioxidants were determined in representative random samples of middle-aged men from 16 European study populations which differed up to 6-fold in age-specific mortality from ischaemic heart disease (IHD). " 05/01/2008 - "The corollary of this situation is that antioxidants must be a benign force to protect the population from the modern scourge of heart disease. " Order ALL the reference details at left...
10.	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/01/1995 - "We report the clinical efficacy of low dosage inhaled nitric oxide and investigate the relationship between its effect and hemodynamic parameters in 18 patients with congenital heart disease. " 06/01/2006 - "Nitric oxide (NO) has been the topic of many studies regarding its therapeutic benefit in patients with cardiac disease. " 06/01/2000 - "This study was performed to determine whether inhaled nitric oxide decreases the incidence of pulmonary hypertensive crises after corrective procedures for congenital heart disease. " 06/01/2000 - "Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease." 04/01/1994 - "This study demonstrates that inhaled nitric oxide exerts a selective pulmonary vasodilation without decreasing systemic arterial pressure in children with congenital heart disease. " Order ALL the reference details at left...

Therapies and Procedures

1.	Heart Transplantation (Grafting, Heart) 11/01/2007 - "BACKGROUND: Despite being accepted as the best treatment for end-stage heart diseases, the long-term benefit of heart transplantation in children remains a matter of controversial debate. " 03/01/2000 - "Cardiac transplantation provides the best option for neonates with congenital heart disease that is not amenable to surgical repair or palliation. " 02/01/1999 - "With a survival rate of 70% at 3 years, cardiac transplantation is the best treatment for end-stage heart disease. " 10/01/1993 - "Our data demonstrate that after heart transplantation prognosis of end-stage cardiac disease is highly improved either for life expectancy and for quality of life. " 01/01/1991 - "Orthotopic heart transplantation continues to be a highly successful therapy for end-stage cardiac disease. " Order ALL the reference details at left...
2.	Stents 01/01/2005 - "CONCLUSIONS: Stent implantation is a technically feasible, safe and effective palliative option in high-risk surgical patients with congenital heart disease and reduced pulmonary blood flow. " 09/01/2004 - "Transcatheter stent implantation for treatment of a significant residual PPAS after surgical correction of complicated congenital heart disease is a safe and effective procedure. " 09/01/2001 - "The purpose of the present study was to assess the usefulness of balloon expandable Palmaz intravascular stents in the transcatheter treatment of children and young adults with native and recurrent coarctation of the aorta, and to develop an improved intravascular stent and balloon delivery catheter specifically developed for vascular obstructions associated with congenital heart disease, including coarctation of the aorta. " 10/01/2008 - "Usefulness of multidetector CT imaging to assess vascular stents in children with congenital heart disease: an in vivo and in vitro study." 05/01/2008 - "The objectives of this study were to evaluate the safety, efficacy, and outcomes of palliative percutaneous stent placement in infants with congenital heart disease (CHD). " Order ALL the reference details at left...
3.	Electric Countershock (Cardioversion) 09/01/1997 - "We conclude that low energy "unipolar" internal cardioversion is a simple, safe, and effective technique for termination of chronic AF in patients with heart disease. " 08/01/1994 - "In patients who were in sinus rhythm both those with and without underlying heart disease improved, and improvement was not related to functional capacity or left ventricular function before cardioversion. " 05/11/2005 - "The study group, comprised of 81 patients with persistent AF, with underlying hypertensive heart disease, consecutively referred for elective direct current cardioversion. " 05/01/2003 - "The aim of the study was to evaluate the time course of atrial and ventricular function improvement following internal atrial cardioversion in patients with structural heart disease. " 12/01/2008 - "Clinical effectiveness of antiarrhythmic treatment after electrical cardioversion in patients without structural heart disease." Order ALL the reference details at left...
4.	Cardiopulmonary Bypass (Heart-Lung Bypass) 01/01/2009 - "Surgical outcomes for patients with congenital heart disease have improved dramatically over the past few decades due, in part, to improvements in preoperative and postoperative management, cardiopulmonary bypass and intraoperative technique, and the development of pediatric cardiology as a subspecialty. " 12/01/1995 - "Although these data suggest that the leukocyte filter offers little clinical benefit, a prospective, randomized study should be undertaken to further elucidate the efficacy of leukocyte depletion for infants undergoing cardiopulmonary bypass for correction of congenital heart disease." 12/01/2004 - "OBJECTIVE: The aim of our study was to investigate the systemic inflammatory response in children with congenital heart disease undergoing surgical correction with cardiopulmonary bypass. " 07/01/2004 - "The objective of this prospective, observational study with consecutive sampling was to assess the reliability, bias, and precision of Nellcor N-395 (N) and Masimo SET Radical (M) pulse oximeters in children with cyanotic congenital heart disease and children with congenital heart disease recovering from cardiopulmonary bypass-assisted surgery admitted to a cardiovascular operating suite and pediatric intensive care unit at a tertiary care community hospital. " 01/01/2004 - "The purpose of this study was to evaluate the effect of pH strategies on cerebral oxygenation and systemic pulmonary collateral circulation during hypothermic cardiopulmonary bypass in cyanotic patients with heart disease. " Order ALL the reference details at left...
5.	Drug Therapy (Chemotherapy) 01/01/2000 - "High prevalence and coexistence of lipid disturbances and ischaemic heart disease (IHD) presents a new challenge to safe and effective pharmacotherapy in this group of patients. " 01/01/2002 - "A key aspect to the safe and effective anaesthetic management of the elderly patient with cardiac disease is a careful preoperative assessment and optimisation of pre-existing drug therapies. " 09/01/1975 - "Proceeding from a dynamic observation of the tolerance of physical exercises in the process of drug therapy of 90 patients with ischaemic heart disease the author concludes that a certain dissociation exists between the subjective effect of the antianginal drugs and the results of bicycle tests in the evaluation of the efficacy of the treatment. " 01/01/2007 - "Two studies were made of the prognostic impact of non-observance of treatment which seems to be associated with an extra-mortality even when the treatment is placebo: the probable explanation is that the non-observance of drug therapy is also associated with the non observance of dietary/life style measures and with cognitive dysfunction associated with more severe cardiac disease. " 07/01/1999 - "This study is also a review of the recent literature and it recommend to take care in prescribing chemotherapy to patients with heart disease history." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Heart Diseases

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 515 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>